Ligachem Biosciences Inc. landed another exclusive licensing deal to develop and commercialize antibody-drug conjugates (ADCs), this time with T-cell receptor therapy specialist Daan Biotherapeutics Inc. for a cancer-targeting antibody.
The market took a strong liking to the latest U.S. FDA guidance for Moleculin Biotech Inc.’s upcoming Miracle phase III trial testing annamycin in cancer. So much so that the company’s stock (NASDAQ:MBRX) soared 202% on Feb. 13 to close at $1.27 a share.
Coming as no surprise, the U.S. Senate’s Feb. 13 confirmation of Robert Kennedy as the next secretary of the Department of Health and Human Services (HHS) did nothing to ease the uncertainty hanging over the FDA and other HHS agencies.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Crispr, Hefei Tianhui, Kenai, Merck, Neuphoria, Nkure, Octavian, Oramed, Oratech, Statera, Tivic Health.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Crispr, Hefei Tianhui, Kenai, Merck, Neuphoria, Nkure, Octavian, Oramed, Oratech, Statera, Tivic Health.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alto, Anaptysbio, Aptose, Gensight, Inovio, Ocugen, Urogen.
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 (F18-Pivalate) successfully detected brain metastases in a variety of primary solid tumors in a phase II study.
RSS
